PIQ: Diagnostic Test Developer - Medicare Says Yes, But Will Doctors?
PIQ: Diagnostic Test Developer - Medicare Says Yes, But Will Doctors?
In a Nutshell
Executive Summary
In a Nutshell
Proteomics International is a pre-revenue diagnostic test developer launching PromarkerD (diabetic kidney disease screening) in March 2025, with Medicare reimbursement already secured at US$390.75. At A$0.43 versus fair value US$1.46 (A$2.35), the stock offers 240-446% upside depending on currency. The key question is whether physician adoption follows the successful Cologuard playbook (5-7 years to 5% market share) or stalls amid a crowded testing landscape, with just 16 months of cash runway creating execution urgency.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★☆☆☆☆ | No dividends and won't be for years. The company is pre-revenue and burning $13.8m annually. Forecasts show break-even in FY28 and profitability by FY30, meaning dividend consideration is 5+ years away. Entirely unsuitable for income investors seeking current yield. |
| Value | ★★★★★ | Trading at 1.1× FY30 EV/Revenue versus peer median 5.8× (79% discount) despite Medicare reimbursement secured. Current A$0.43 implies market assigns only 15% probability to successful commercialisation versus our 60% base case. Fair value US$1.46 offers 240% upside with downside limited to $0.47 liquidation floor (4.3:1 reward/risk). Extreme pessimism creates asymmetric opportunity if Q1 FY26 test volumes validate adoption trajectory. |
| Growth | ★★★★☆ | Revenue forecast to surge from $1m services (FY25) to $332m by FY30 (86% CAGR). Platform technology leverages single Promarker system across four tests, addressing $130bn+ combined TAM (diabetic kidney disease $90bn, esophageal cancer $35bn, endometriosis $20bn). Operating leverage delivers margin expansion from -17% to +18% EBITDA as fixed costs spread. Main risk: pre-revenue execution uncertainty (7.5/10 management credibility reflects technical strength but unproven commercial track record). |
| Quality | ★★★☆☆ | Business quality scores 6.5/10 (below peer 7.2/10 average), reflecting untested commercial operations despite strong innovation (27 patents, clinical validation published). Narrow moat (5.3/10) lasts 5-7 years via patent protection before Quest Diagnostics/Labcorp commoditise protein biomarkers (terminal margins compress from 70% to 60% gross). Management delivers technical milestones (AUC 0.88 achieved, Medicare code secured) but commercial timelines historically slip (PromarkerD delayed 2020→2025). Adequate for quality-conscious investors accepting early-stage discount. |
| Thematic | ★★★★☆ | Captures three secular themes: precision medicine (molecular diagnostics 15% CAGR through 2035), value-based care (Medicare prioritises preventative tests saving $90k/year dialysis costs), and ageing demographics (diabetes prevalence +1.2% annually). First-mover in protein-based predictive diagnostics globally. Digital platform (MyTest.Health) bypasses physician referral bottlenecks. Strong thematic fit, though binary execution risk (60% base case versus 40% downside scenarios) requires conviction in healthcare innovation cycle. |
Best fit: Value investors with biotech risk tolerance. The 79% discount to peer multiples despite reimbursement de-risking creates classic deep value setup. Medicare approval removes primary commercial uncertainty (pricing anchor $390.75 versus $310 for commodity A1C test). However, this requires stomach for 16-month cash runway and pre-revenue volatility. Position sizing discipline essential—0.5-1.0% portfolio weight captures 4.3:1 upside/downside asymmetry without undue concentration risk.
Executive Summary
Proteomics International develops diagnostic blood tests using protein biomarkers. The company's PromarkerD test predicts diabetic kidney disease four years in advance, targeting the 10 million high-risk US diabetics who currently rely on reactive monitoring. Revenue comes from analytical services ($1m annually, capacity-constrained) until test sales commence March-June 2025. The platform technology supports four distinct tests from a single laboratory system, reducing per-test development costs 30-40% versus peers.
Recent performance shows operational execution on track but financial stress mounting. Management secured Medicare reimbursement at US$390.75 in November 2025 (26% premium to commodity A1C test), validated clinical data across three independent cohorts (857+ patients, AUC 0.88), and prepared commercial infrastructure. However, cash burn accelerated to $13.8m in FY25 versus $11.5m prior year, leaving 16 months runway. Services revenue grew modestly 8% to $1m, immaterial to valuation.
The investment case centres on commercialisation execution. Base case (60% probability) assumes physician adoption follows Cologuard's 5-7 year trajectory to 5% market penetration, delivering terminal revenue of $616m and EBITDA margins compressing from 18% peak to 15% as Quest Diagnostics/Labcorp enter 2028-30. Bear case (30% probability) models adoption lag triggering cash crisis Q4 FY26, requiring dilutive refinancing. Severe case (10% probability) captures outright commercial failure. Dynamic weighted valuation integrates DCF (34% weight), transaction comparables (37% weight, Blueprint Genetics $425m precedent), trading multiples (19% weight), and asset floor (10% weight). At A$0.43 versus fair value US$1.46, the stock is undervalued by 240% in US dollar terms.
Results & Outlook
What happened?
FY25 results show technical milestones achieved but financial pressure building. Revenue reached $1m (up 8%), entirely from analytical services to pharmaceutical clients. The company secured Medicare reimbursement code at US$390.75 in November 2025, validated PromarkerD clinical performance (AUC 0.88 across 857 patients), and obtained ISO 15189/CLIA certifications for commercial launch. Cash burn increased to $13.8m from $11.5m as the company prepared sales infrastructure. The balance sheet holds $11m cash (16 months runway) with zero debt. PromarkerEso (esophageal cancer test) achieved 91% sensitivity in validation studies, preparing for H2 CY25 launch.
| Metric | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Revenue ($m) | 0.96 | 9.4 | 35.6 | 99.7 |
| EBITDA ($m) | (13.2) | (1.6) | (0.4) | 12.0 |
| EBITDA Margin (%) | N/M | (17%) | (1%) | 12% |
| EPS ($/share) | (0.084) | (0.011) | (0.006) | 0.036 |
| Free Cash Flow ($m) | (13.8) | (3.9) | (4.1) | 0.3 |
| Test Volume (000s) | 0 | 15 | 52 | 125 |
What's next?
PromarkerD launches March-June 2025 through California pilot program, targeting 1,000+ tests per quarter by Q2 FY26. Private payer coverage decisions follow through Q2-Q4 FY26 (base case assumes 75-85% approval replicating Medicare precedent). Operating leverage drives profitability inflection—break-even at $100m revenue (FY28), then margins expand to 18% EBITDA by FY30 as fixed costs spread over growing test volumes. Three pipeline tests launch sequentially: PromarkerEso (esophageal cancer, H2 CY25), PromarkerEndo (endometriosis, FY27), OxiDx (equine, concurrent). Near-term catalyst: Q1 FY26 test volume disclosure validates or refutes physician adoption thesis. Bear case trigger: volumes below 500/quarter indicate commercial failure, forcing dilutive capital raise Q4 FY26 at estimated $0.30/share (+20% share dilution). Quest Diagnostics/Labcorp competitive response expected 2028-30, compressing terminal margins from 18% to 15% EBITDA as protein biomarker testing commoditises.
Valuation & Risks
| Metric | Value |
|---|---|
| Fair Value | US$1.46 / A$2.35 |
| Current Price | A$0.43 |
| Upside | +240% (USD) / +446% (AUD) |
| 90% Confidence Interval | US$1.10 – $1.83 |
| Reliability Score | 68/100 (Medium) |
| Base Case (60% prob.) | US$1.91 |
| Bear Case (30% prob.) | US$0.93 |
| Severe Case (10% prob.) | US$0.47 |
What could go wrong?
The single biggest risk is physician adoption failure within the 16-month cash runway. PromarkerD competes against entrenched A1C standard-of-care testing ($310 commodity alternative with 100% physician familiarity versus <1% PIQ awareness). Educating doctors costs an estimated $5,000 per adopter, requiring meaningful test volumes by Q4 FY26 to avoid dilutive refinancing. Historical precedent shows Cologuard took 5-7 years to reach 5% penetration despite Exact Sciences' $500m pre-launch marketing budget—PIQ has $1-2m annually. If Q1-Q2 FY26 volumes fall below 500 tests per quarter (versus 1,000+ target), the Bear case crystallises: fair value drops to $0.93 (116% upside versus 240% base), cash crisis forces equity raise at $0.30/share, and share count increases 20% from 216.5m to 243.5m. This scenario carries 30% probability. The market's current $0.43 pricing implies even greater pessimism—reverse-engineering suggests 50% severe case probability (adoption failure <1% penetration, fair value $0.47) versus our 10% assessment. Monitoring point: monthly test volume disclosures starting Q1 FY26 provide early warning system.